Immunovant
IMVT · NASDAQ
Bulios Fair Price
$17.5
47.7% downside
Current Price
$33.49
According to Bulios Fair Price, IMVT is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Immunovant, Inc. is an American biotechnology company focused on the development of innovative immunotherapies for the treatment of autoimmune diseases. The company specializes in the development of monoclonal antibodies that target specific immune pathways, which can help patients suffering from conditions such as myasthenia gravis, autoimmune hemolytic anemia, and others. Immunovant aims to provide effective therapeutic options for patients whose current treatments are insufficient or associated with undesirable side effects.
Sector
Healthcare
Industry
Biotechnology
CEO
Eric Venker
Employees
315
Headquarters
Durham
Upcoming events
Earnings
Upcoming earnings report